Vangsted AJ - Search Results

1

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group.

Gregersen H, Peceliunas V, Remes K, Schjesvold F, Abildgaard N, Nahi H, Andersen NF, Vangsted AJ, Klausen TW, Helleberg C, Carlson K, Frølund UC, Axelsson P, Stromberg O, Blimark CH, Crafoord J, Tsykunova G, Eshoj HR, Waage A, Hansson M, Gulbrandsen N. Gregersen H, et al. Among authors: vangsted aj. Eur J Haematol. 2022 Jan;108(1):34-44. doi: 10.1111/ejh.13709. Epub 2021 Oct 11. Eur J Haematol. 2022. PMID: 34536308 Free PMC article. Clinical Trial.

2

Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation.

Vangsted A, Gimsing P, Klausen TW, Nexø BA, Wallin H, Andersen P, Hokland P, Lillevang ST, Vogel U. Vangsted A, et al. Int J Cancer. 2007 Mar 1;120(5):1036-45. doi: 10.1002/ijc.22411. Int J Cancer. 2007. PMID: 17131345 Free article.

3

[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].

Lund T, Gregersen H, Vangsted A, Marker P, Abildgaard N. Lund T, et al. Ugeskr Laeger. 2009 Jan 5;171(1-2):50-2. Ugeskr Laeger. 2009. PMID: 19128568 Danish.

4

A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support.

Vangsted AJ, Klausen TW, Gimsing P, Andersen NF, Abildgaard N, Gregersen H, Vogel U. Vangsted AJ, et al. Haematologica. 2009 Sep;94(9):1274-81. doi: 10.3324/haematol.2008.004572. Haematologica. 2009. PMID: 19734419 Free PMC article. Clinical Trial.

5

Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004.

Vangsted AJ, Klausen TW, Andersen NF, Abildgaard N, Gang AO, Gregersen H, Vogel U, Gimsing P. Vangsted AJ, et al. Eur J Haematol. 2010 Sep;85(3):209-16. doi: 10.1111/j.1600-0609.2010.01465.x. Epub 2010 May 5. Eur J Haematol. 2010. PMID: 20477864

6

No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.

Vangsted AJ, Søeby K, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Vogel U, Werge T, Rasmussen HB. Vangsted AJ, et al. BMC Cancer. 2010 Aug 4;10:404. doi: 10.1186/1471-2407-10-404. BMC Cancer. 2010. PMID: 20684753 Free PMC article.

7

Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.

Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisløff F. Gimsing P, et al. Lancet Oncol. 2010 Oct;11(10):973-82. doi: 10.1016/S1470-2045(10)70198-4. Lancet Oncol. 2010. PMID: 20863761 Clinical Trial.

8

The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP.

Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gregersen H, Nexø BA, Vogel UB. Vangsted AJ, et al. Ann Hematol. 2011 Jun;90(6):675-84. doi: 10.1007/s00277-010-1105-z. Epub 2010 Nov 3. Ann Hematol. 2011. PMID: 21046104

9

Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.

Vangsted AJ, Klausen TW, Abildgaard N, Andersen NF, Gimsing P, Gregersen H, Nexø BA, Vogel U. Vangsted AJ, et al. Ann Hematol. 2011 Oct;90(10):1173-81. doi: 10.1007/s00277-011-1194-3. Epub 2011 Feb 24. Ann Hematol. 2011. PMID: 21347685

10

Genetic variations in multiple myeloma II: association with effect of treatment.

Vangsted A, Klausen TW, Vogel U. Vangsted A, et al. Eur J Haematol. 2012 Feb;88(2):93-117. doi: 10.1111/j.1600-0609.2011.01696.x. Epub 2011 Nov 16. Eur J Haematol. 2012. PMID: 21883476 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

100 results

Search Page